Whole genome expression profiling of blood cells in ovarian cancer patients -Prognostic impact of theCYP1B1,MTSS1,NCALD, andNOP14genes

Isaksson, Helena S.; Sorbe, Bengt; Nilsson, Torbjörn

doi:10.18632/oncotarget.1938

Cited by 27 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the tumor suppressor role of NOP14 in breast cancer, survival analysis suggested that low NOP14 expression is associated with poor patient outcome (Figure 6 ). Another analogous finding was recently made in ovarian cancer, where NOP14 overexpression in blood was associated with better survivals [ 27 ]. These suggest that NOP14 expression may be an applicable prognostic biomarker for breast cancer.…”

Section: Discussionsupporting

confidence: 75%

NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway

et al. 2015

View full text Add to dashboard Cite

NOP14, which is functionally conserved among eukaryotes, has been implicated in cancer development. Here, we show that NOP14 is poorly expressed in breast cancer cells and invasive breast cancer tissues. In vivo and in vitro studies indicated that NOP14 suppressed the tumorigenesis and metastasis of breast cancer cells. Further investigations revealed that NOP14 enhanced ERα expression and inhibited the Wnt/β-catenin pathway by up-regulating NRIP1 expression. Survival analysis indicated that low NOP14 expression was significantly associated with poor overall survival (P = 0.0006) and disease-free survival (P = 0.0007), suggesting that NOP14 is a potential prognostic factor in breast cancer. Taken together, our findings reveal that NOP14 may suppress breast cancer progression and provide new insights into the development of targeted therapeutic agents for breast cancer.

show abstract

Section: Discussionsupporting

confidence: 75%

NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It has been revealed 13 that NCALD was significantly downregulated in several solid cancers and a low level of NCALD implied shorter survival in patients with lung cancer. In OC, a low level of NCALD in the whole blood of 33 patients significantly related to poor survival 48 . Consistently, we found that low expression of NCALD predicted poor OS, PFS, and PPS in a cohort of 1815 OC tissues according to Kaplan‐Meier plotter 18 (Figure 2A).…”

Section: Discussionsupporting

confidence: 71%

NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer

Dong

Yin

Zhu

et al. 2020

J of Cellular Biochemistry

View full text Add to dashboard Cite

Drug resistance, an impenetrable barrier in the treatment of ovarian cancer (OC), is often associated with poor outcomes. Hence, it is urgent to discover new factors controlling drug resistance and survival. The association between neurocalcin delta (NCALD) and cancer drug resistance is poorly understood. Here, we reveal that NCALD messenger RNA expression, probably regulated by DNA methylation and microRNAs, was significantly downregulated in at least three independent microarrays covering 633 ovarian carcinomas and 16 normal controls, which includes the Cancer Genome Atlas (TCGA) ovarian cohort. In the sub‐groups of the TCGA cohort, NCALD was suppressed in 90 platinum‐resistant tissues vs in 197 sensitive tissues. It is consistent with the quantitative reverse transcription polymerase chain reaction results revealing gene downregulation in carboplatin‐resistant SKOV3 and HeyA8 OC cells as compared with that in controls. Low expression of NCALD predicted poor overall survival (OS) in sub‐groups of 1656 patients, progression‐free survival (PFS) in 1435 patients, and post‐progression survival (PPS) in 782 patients according to Kaplan‐Meier plotter covering 1815 OC patients. Comprehensive bioinformatic analyses strongly implicated NCALD in the regulation of drug resistance, probably via competing for endogenous RNA (ceRNA) interactions with CX3CL1 and tumor immune‐microenvironment. NCALD acted as a ceRNA for CX3CL1 in 21 different cancers includes OC according to Starbase. These two genes negatively correlated with tumor purity and positively correlated with infiltration levels of neutrophils and dendritic cells in OC. The combined low expression of NCALD and CX3CL1 showed better prognosis potential for OS, PFS, and PPS in the 1815 OC patients than any of the individually tested genes. In summary, NCALD acts as a ceRNA for CX3CL1, and its downregulation may affect drug resistance and prognosis in OC. Thus, NCALD could be a new therapeutic target for anticancer therapy and a new biomarker for survival prediction in OC.

show abstract

“…MTSS1 has previously been shown to be downregulated in metastases of a variety of solid tumors. Moreover, low MTSS1 expression levels confer a poorer prognosis in breast and ovarian cancer and higher expression levels correlate with improved overall survival rates [ 7 , 8 ]. The prognostic value of MTSS1 expression has also been demonstrated for esophageal squamous cell carcinoma in which patients with high MTSS1 expression levels had a favorable prognosis compared to those who had reduced MTSS1 expression levels [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia

et al. 2015

View full text Add to dashboard Cite

The adapter protein metastasis suppressor 1 (MTSS1) is implicated as a tumor suppressor or tumor promoter, depending on the type of solid cancer. Here, we identified Mtss1 expression to be increased in AML subsets with favorable outcome, while suppressed in high risk AML patients. High expression of MTSS1 predicted better clinical outcome of patients with normal-karyotype AML. Mechanistically, MTSS1 expression was negatively regulated by FLT3-ITD signaling but enhanced by the AML1-ETO fusion protein. DNMT3B, a negative regulator of MTSS1, showed strong binding to the MTSS1 promoter in PML-RARA positive but not AML1-ETO positive cells, suggesting that AML1-ETO leads to derepression of MTSS1. Pharmacological treatment of AML cell lines carrying the FLT3-ITD mutation with the specific FLT3 inhibitor PKC-412 caused upregulation of MTSS1. Moreover, treatment of acute promyelocytic cells (APL) with all-trans retinoic acid (ATRA) increased MTSS1 mRNA levels. Taken together, our findings suggest that MTSS1 might have a context-dependent function and could act as a tumor suppressor, which is pharmacologically targetable in AML patients.

show abstract

Whole genome expression profiling of blood cells in ovarian cancer patients -Prognostic impact of theCYP1B1,MTSS1,NCALD, andNOP14genes

Cited by 27 publications

References 38 publications

NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway

NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway

NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia

Contact Info

Product

Resources

About